BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26187616)

  • 1. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
    Gupta S; Argilés G; Munster PN; Hollebecque A; Dajani O; Cheng JD; Wang R; Swift A; Tosolini A; Piha-Paul SA
    Clin Cancer Res; 2015 Dec; 21(23):5235-44. PubMed ID: 26187616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.
    Piha-Paul SA; Munster PN; Hollebecque A; Argilés G; Dajani O; Cheng JD; Wang R; Swift A; Tosolini A; Gupta S
    Eur J Cancer; 2015 Sep; 51(14):1865-73. PubMed ID: 26199039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.
    Brana I; Berger R; Golan T; Haluska P; Edenfield J; Fiorica J; Stephenson J; Martin LP; Westin S; Hanjani P; Jones MB; Almhanna K; Wenham RM; Sullivan DM; Dalton WS; Gunchenko A; Cheng JD; Siu LL; Gray JE
    Br J Cancer; 2014 Nov; 111(10):1932-44. PubMed ID: 25290091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
    Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
    J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).
    Meulenbeld HJ; de Bono JS; Tagawa ST; Whang YE; Li X; Heath KH; Zandvliet AS; Ebbinghaus SW; Hudes GR; de Wit R
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):909-16. PubMed ID: 23921574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
    Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
    J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.
    Seiler M; Ray-Coquard I; Melichar B; Yardley DA; Wang RX; Dodion PF; Lee MA
    Clin Breast Cancer; 2015 Feb; 15(1):60-5. PubMed ID: 25239224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
    Yap TA; Yan L; Patnaik A; Fearen I; Olmos D; Papadopoulos K; Baird RD; Delgado L; Taylor A; Lupinacci L; Riisnaes R; Pope LL; Heaton SP; Thomas G; Garrett MD; Sullivan DM; de Bono JS; Tolcher AW
    J Clin Oncol; 2011 Dec; 29(35):4688-95. PubMed ID: 22025163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.
    Pearson AD; Federico SM; Aerts I; Hargrave DR; DuBois SG; Iannone R; Geschwindt RD; Wang R; Haluska FG; Trippett TM; Geoerger B
    Oncotarget; 2016 Dec; 7(51):84736-84747. PubMed ID: 27713169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.
    Gore L; Trippett TM; Katzenstein HM; Boklan J; Narendran A; Smith A; Macy ME; Rolla K; ; Narashimhan N; Squillace RM; Turner CD; Haluska FG; Nieder M
    Clin Cancer Res; 2013 Jul; 19(13):3649-58. PubMed ID: 23659969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
    Rugo HS; Trédan O; Ro J; Morales SM; Campone M; Musolino A; Afonso N; Ferreira M; Park KH; Cortes J; Tan AR; Blum JL; Eaton L; Gause CK; Wang Z; Im E; Mauro DJ; Jones MB; Denker A; Baselga J
    Breast Cancer Res Treat; 2017 Oct; 165(3):601-609. PubMed ID: 28681171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
    Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
    Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
    Jänne PA; Cohen RB; Laird AD; Macé S; Engelman JA; Ruiz-Soto R; Rockich K; Xu J; Shapiro GI; Martinez P; Felip E
    J Thorac Oncol; 2014 Mar; 9(3):316-23. PubMed ID: 24496004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
    Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.
    Mita MM; Poplin E; Britten CD; Tap WD; Rubin EH; Scott BB; Berk L; Rivera VM; Loewy JW; Dodion P; Haluska F; Sarantopoulos J; Mita A; Tolcher A
    Ann Oncol; 2013 Apr; 24(4):1104-11. PubMed ID: 23211938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers.
    Nemunaitis J; Hochster HS; Lustgarten S; Rhodes R; Ebbinghaus S; Turner CD; Dodion PF; Mita MM
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):336-42. PubMed ID: 23615181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
    Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
    J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
    Papadopoulos KP; Tabernero J; Markman B; Patnaik A; Tolcher AW; Baselga J; Shi W; Egile C; Ruiz-Soto R; Laird AD; Miles D; Lorusso PM
    Clin Cancer Res; 2014 May; 20(9):2445-56. PubMed ID: 24583798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.
    Wisinski KB; Tevaarwerk AJ; Burkard ME; Rampurwala M; Eickhoff J; Bell MC; Kolesar JM; Flynn C; Liu G
    Clin Cancer Res; 2016 Jun; 22(11):2659-67. PubMed ID: 27026198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
    Rodrigues HV; Ke D; Lim J; Stephen B; Bellido J; Janku F; Zinner R; Tsimberidou A; Hong D; Piha-Paul S; Fu S; Naing A; Subbiah V; Karp D; Falchook G; Kurzrock R; Wheler J
    Invest New Drugs; 2015 Jun; 33(3):700-9. PubMed ID: 25902899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.